Crinetics Pharmaceuticals Inc. announced on June 10, 2025, that its Compensation Committee has approved inducement grants under the 2021 Employment Inducement Incentive Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The company has awarded non-qualified stock options to purchase a total of 74,000 shares of common stock and 48,850 restricted stock units (RSUs) to 20 new non-executive employees. The stock options are priced at $33.08 per share, matching the closing price on the Nasdaq Global Select Market as of June 10, 2025. Both the stock options and RSUs will vest over four years, contingent upon the employees' continued employment with Crinetics. These grants are part of a strategy to attract new talent to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.